Tenecteplase

Tenecteplase, sold as TNKase, is a clot-dissolving medicine, a tissue plasminogen activator, given into a vein. The US label read lists two uses, both in adults: the treatment of acute ischemic stroke, and reducing the risk of death associated with acute ST-elevation myocardial infarction (STEMI). The label says it binds to fibrin and converts plasminogen to plasmin.

Also called TNKase · TNK-tPA

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 259280; MeSH descriptor D000077785 is Tenecteplase. It is a biologic: the openFDA record carries no UNII, and RxClass returned no FDA class for it, so the class rests on the label's own words (it calls tenecteplase a tissue plasminogen activator and refers to related thrombolytic agents), and MeSH lists Fibrinolytic Agents (D005343) among its pharmacological actions. The label read is the Genentech, Inc. label for TNKase, application BLA103909, effective 2025-12-15 in openFDA. This page records label indications and the class only: no trial result and no dose is given. This is a regulatory record, not a finding about how well the medicine works.

Trials at a glance

The figures count the 51 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
51
Phase 3 or 4
39
Recruiting
18
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingCompletedTerminatedUnknown statusAll statuses
Phase 2206019
Phase 2/3201003
Phase 3136113336
Phase 4101013
All phases186193551

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 25 more.

About this drug

Level
Substance
Mechanism
The label says tenecteplase is a modified form of human tissue plasminogen activator that binds to fibrin and converts plasminogen to plasmin.

Claims and evidence

Context Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction

Recipient
Adult
Population
Adult patients described in the indications sections of the label.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the passages read state
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of TNKase (tenecteplase), in the Genentech, Inc. version dated 2025-12-15 in openFDA, describes the medicine as a tissue plasminogen activator (tPA) and lists it, in adults, for the treatment of acute ischemic stroke (AIS) and to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).

    Applies to Adult Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; time limits, contraindications, doses, interactions and bleeding warnings were not read. openFDA also lists a second TNKase record with only the myocardial infarction indication. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Supports openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2025-12-15
      Source state
      Current
      Version fingerprint
      5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.

      Locator
      results[0].indications_and_usage[0], 1.1 Acute Ischemic Stroke
      How it applies
      Label passage quoted in the research quote table (LB-05).
      Retrieved
      Source effective date
      2025-12-15
      Source state
      Current
      Version fingerprint
      5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.

      Locator
      results[0].indications_and_usage[0], 1.2 Acute ST Elevation Myocardial Infarction
      How it applies
      Label passage quoted in the research quote table (LB-06).
      Retrieved
      Source effective date
      2025-12-15
      Source state
      Current
      Version fingerprint
      5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Background openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20251215.
      Retrieved
      Source effective date
      2025-12-15
      Source state
      Current
      Version fingerprint
      5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

TNKASE

No label from the application holder was found in the openFDA label dataset for application BLA103909. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval BLA103909 TNKASE
  2. Supplemental approval BLA103909 TNKASE

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 1

  • A biologics license application (BLA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductBLA103909

Registry trials 51

Record details

Record id
cardio:tenecteplase
Content hash
f3cea7d45e4c539a8b89bfed9214be34c8d55a1d72b93a649ed526bc94fc6f6a